Ewing's sarcoma cancer stem cell targeted therapy

Area of Science:

• Oncology
• Cancer Stem Cell Biology
• Molecular Genetics

Background:

• Ewing sarcoma (ES) family of tumors (ESFTs) are aggressive round cell tumors affecting children and young adults.
• Understanding the cellular origins and molecular drivers of ESFTs is crucial for developing effective therapies.

Purpose of the Study:

• To review current findings on Ewing sarcoma cancer stem cell (CSC) targeted therapy.
• To discuss prognostic factors, genetic origins, epigenetic mechanisms, and therapeutic strategies for ESFTs.

Main Methods:

• Literature review of studies on ESFTs, CSCs, and targeted therapies.
• Analysis of research on ESFT histogenesis, pathogenesis, and molecular alterations.
• Examination of potential therapeutic targets, including CSC markers, immune targeting, and novel drugs.

Main Results:

• ESFTs may originate from Mesenchymal stem cells (MSCs) or Neural crest stem cells (NCSCs), which are permissive to EWS-FLI1 expression.
• ES CSCs share microRNA profiles with embryonic stem cells (ESCs) and CSCs from other cancers.
• EWS-FLI1 oncogenic activity offers potential for new biomarkers and targeted anticancer agents.

Conclusions:

• Targeting ES CSCs holds promise for novel therapeutic strategies against ESFTs.
• The link between EWS function, stem cells, senescence, and tumorigenesis provides avenues for cancer and aging research.
• Further research into EWS fusion regulatory mechanisms can lead to improved prognostic biomarkers and treatments.